Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors
International Journal of Molecular Sciences · 27.10.2026 · 27 (21) · 9616
DOI: 10.3390/ijms27219616 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.10.2026. Verfasst von Errikos Petsas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece. Hauptthemen laut MEDLINE: Indoles, Receptor-Interacting Protein Serine-Threonine Kinases, Imidazoles, Protein Kinase Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) regulates necroptotic cell death and sterile inflammation, representing an established therapeutic target for degenerative and inflammatory disorders. Here, three putative hydantoin-based analogues bearing distinctive N-substitutions—an ethylcyclobutyl derivative (Compound 1), an ethoxyphenylethyl analogue (Compound 2), and a 5-chloroindole (3-fluoro-4-methylbenzyl) derivative (Compound 3)—were investigated against the prototypical inhibitor Necrostatin-1 using virtual screening, induced-fit docking, 500 ns molecular dynamics simulations and pharmacokinetic profiling. Induced Fit Docking within the RIPK1 kinase domain indicated that Compound 3 (−9.1 kcal/mol) and Compound 1 (−7.9 kcal/mol) achieved favorable predicted binding scores surpassing Necrostatin-1 (−7.3 kcal/mol), whereas Compound 2 displayed a considerably weaker binding score (−4.1 kcal/mol). All-atom molecular dynamics simulations revealed that Compound 1 maintained high dynamic stability with ligand RMSD constrained to 1.2–2.0 Å and sustained hydrogen bonding with Leu157. Conversely, Compound 2 dissociated from the primary binding pocket, while Compound 3 deviated from its initial docking pose (RMSD 7.0–9.2 Å) to engage a secondary interaction network with Asn170, Glu171 and Lys45. In silico ADME profiling predicted that all three candidates comply with Lipinski and Veber drug-likeness criteria with high predicted intestinal absorption. These computational findings provide putative structural insights into kinase-ligand interactions, prioritizing candidate molecules for chemical synthesis and in vitro biological evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
ORCID-Profile: Errikos Petsas, Christos T Chasapis
Zitieren
APA
Petsas, E., & Chasapis, C. T. (2026). Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors. International Journal of Molecular Sciences, 27(21), 9616. https://doi.org/10.3390/ijms27219616
Vancouver
Petsas E, Chasapis CT. Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors. International Journal of Molecular Sciences. 2026;27(21):9616. doi:10.3390/ijms27219616
BibTeX
@article{Petsas2026,
author = {Petsas, Errikos and Chasapis, Christos T},
title = {Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9616},
doi = {10.3390/ijms27219616}
}
EUVIMED